Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Hough CL, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Martinez A, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Goyal A, DeLamielleure LE, DeCuir J, Surie D, Dawood FS, Tenforde MW, Uyeki TM, Garg S, Ellington S, Self WH. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clin Infect Dis. 2025 Aug 01; 81(1):190-197.
-
Meister TL, Nocke MK, Heinen N, Burkard TL, Br?ggemann Y, Westhoven S, Tr?eb B, Ebert N, Thomann L, Lubieniecki KP, Lubieniecka JM, D?ring K, Herrmann M, Haid S, Pietschmann T, Wiegmann B, Tao R, Pfefferle S, Addo MM, Thiel V, Drexler I, Babel N, Phuc Nguyen H, Brown RJP, Todt D, Steinmann E, Pfaender S. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants. Proc Natl Acad Sci U S A. 2025 Jul 15; 122(28):e2500276122.
-
Zvornicanin SN, Shaqra AM, Flynn J, Carias Martinez H, Jia W, Moquin S, Dovala D, Bolon DN, Kurt Yilmaz N, Schiffer CA. Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50. mBio. 2025 May 14; 16(5):e0406824.
-
Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, Kiertiburanakul S, Kim AHJ, Longbrake EE, Molina JM, Paredes R, Tucker D, Uriel A, Weinmann-Menke J, Aksyuk AA, Clegg LE, Currie A, Yang H, Flyrin K, Gibbs M, Shroff M, Perez JL, Chang LJ, Cohen TS. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. 2025 Jul; 25(7):813-826.
-
Phan T, Ribeiro RM, Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Tien D, Su K, Reynolds Z, Li Y, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Li JZ, Siedner MJ, Barczak AK, Lemieux JE, Perelson AS. Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance. J Virol. 2025 Mar 18; 99(3):e0162324.
-
Wang Y, Fu Q, Sha S, Yoon S. Interferon inhibitors increase rAAV production in HEK293 cells. J Biotechnol. 2025 Mar; 399:9-18.
-
Bennett FJ, Keilson JM, Turgeon MK, Oppat KM, Warren EAK, Shah SA, Agopian VG, Magliocca JF, Cameron A, Orloff SL, Kubal CA, Cannon RM, Akoad ME, Emamaullee J, Aucejo F, Vagefi PA, Nguyen MH, Dhanireddy K, Kazimi MM, Sonnenday CJ, Foley DP, Abdouljoud M, Sudan DL, Humar A, Doyle MBM, Chapman WC, Maithel SK. Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma. Ann Surg Oncol. 2025 Jan; 32(1):426-437.
-
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Clifford Lane H, Beigel J, Dodd LE. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
-
Azzolino VN, Shaqra AM, Ali A, Kurt Yilmaz N, Schiffer CA. Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance. Viruses. 2024 09 05; 16(9).
-
Tamura TJ, Choudhary MC, Deo R, Yousuf F, Gomez AN, Edelstein GE, Boucau J, Glover OT, Barry M, Gilbert RF, Reynolds Z, Li Y, Tien D, Vyas TD, Passell E, Su K, Drapkin S, Abar EG, Kawano Y, Sparks JA, Wallace ZS, Vyas JM, Shafer RW, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024 09 03; 7(9):e2435431.